FOLH1 and prostate carcinoma: Visceral metastases, platelet dynamics, and PSA decline: from biomarkers to better outcomes in [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu‐PSMA‐617 therapy in metastatic castration-resistant prostate cancer.